New pharmaceutical options for patients with allergic and asthma-related diseases: Balancing effectiveness and safety in selection of specific therapies.

Targeted immunotherapies have expanded treatment options for allergic and immunologic diseases by enabling selective modulation of key inflammatory pathways. However, their growing use necessitates careful evaluation of safety profiles and long-term risks. This review examines the mechanisms of action, safety considerations, and clinical implications of emerging monoclonal antibody and small-molecule therapies used in allergic and immunologic diseases. Monoclonal antibodies targeting IgE, interleukin (IL)-5/IL-5 receptor α (IL-5Rα), IL-4Rα, IL-13, thymic stromal lymphopoietin, and IL-31 demonstrate efficacy across a range of atopic conditions, including asthma, atopic dermatitis, and chronic urticaria. They are generally well tolerated, though they are associated with adverse events such as anaphylaxis, conjunctivitis, eosinophilia, and herpes virus reactivation. Small-molecule therapies, including Janus kinase, Bruton's tyrosine kinase, and phosphodiesterase-4 (PDE4) inhibitors, expand treatment options by targeting intracellular signaling pathways and offering broader immunomodulatory effects. Among these, Janus kinase inhibitors carry boxed warnings for major adverse cardiovascular events, thromboembolism, malignancy, and viral reactivation. Second-generation Bruton's tyrosine kinase inhibitors and PDE4 inhibitors demonstrate comparatively favorable safety profiles, though tolerability may remain an issue for PDE4 inhibitors. Despite promising short-term safety and efficacy, long-term risks still pose a question given the limited longitudinal data. The increasing complexity of therapeutic selection underscores the need for shared decision-making and long-term surveillance to ensure successful therapeutic outcomes while prioritizing patient safety.